Anitoa Systems has added its SARS-CoV-2 Rapid Nucleic Acid Test portfolio to include the detection of Omicron and Delta mutations.
The company released two new test kits: CE-IVD certified SARS-CoV-2 and Delta Variant Kit and research use only (RUO) SARS-CoV-2, Delta, and Omicron Kit. Anitoa combines an in-house portable real time polymerase Chain Reaction (qPCR) instrument called Maverick, with its “one-step” reverse transcription qPCR (RT-qPCR) reagent for testing SARS-CoV-2 and Variants.
This solution eliminates the process of package and transporting patient samples to a central lab and the additional steps of sample-prep prior to running RT-PCR. This saves time and reduces risks of cross-contamination. Anitoa’s portable solution also avoids false-negative readings due to the degradation of viral RNAs in the sample when transported.
With Anitoa’s solution, patient samples, such as throat or nasal swaps, can be applied directly to the portable instrument on-site without the need to freeze, transport and thaw the samples in the lab. The Maverick RT-qPCR device has a 4-plex optical multiplexing subsystem to detect multiple gene targets in one sample, and it take about 45 minutes from sample to results. Maverick is powered by a CMOS biosensor chip developed by Anitoa. The CMOS biosensor integrates many sensing and processing functions necessary for qPCR in a single silicon chip, thus significantly reducing the footprint and cost. Maverick qPCR instrument is CE-certified, and U.S. FDA-registered.
“As a key supplier of equipment and materials for detecting SAR-Cov-2, Anitoa is closely monitoring all current and emerging variants of this deadly virus to ensure that our test solutions are relevant to the need of the people combating this disease” says Zhimin Ding, PhD, CEO of Anitoa Systems.